Fate Therapeutics (FATE) Retained Earnings (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Retained Earnings came in at -$1.6 billion in Q1 2026, down 819745.03% YoY from N/an in Q1 2025, and down 1349687.93% on a QoQ basis from $116000.0 in Q4 2025.
Fate Therapeutics (FATE) Retained Earnings (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Retained Earnings data on file, last reported at -$1.6 billion in Q1 2026.
- Quarterly Retained Earnings fell 819745.03% year-over-year to -$1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 billion (down 819745.03% YoY) and the FY2025 annual result came in at $116000.0, down 56.72% from the prior year.
- Retained Earnings eased to -$1.6 billion in Q1 2026, from $116000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.6 billion in Q4 2023 to a low of -$1.6 billion in Q1 2026.
- A 5-year average of -$412.3 million and a median of -$646000.0 in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings jumped 250.36% — and 2026, when it tumbled 819745.03%.
- Tracing FATE's Retained Earnings over 5 years: stood at -$1.1 billion in 2022, then jumped by 250.36% to $1.6 billion in 2023, then slumped by 99.98% to $268000.0 in 2024, then sank by 56.72% to $116000.0 in 2025, then tumbled by 1349687.93% to -$1.6 billion in 2026.
- The last three Retained Earnings figures came in at -$1.6 billion (Q1 2026), $116000.0 (Q4 2025), and -$1.5 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | -1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.57 Bn |
| Dec 31, 2025 | 116,000.00 |
| Sep 30, 2025 | -1.50 Bn |
| Jun 30, 2025 | -1.47 Bn |
| Mar 31, 2025 | 191,000.00 |
| Dec 31, 2024 | 268,000.00 |
| Sep 30, 2024 | 835,000.00 |
| Jun 30, 2024 | -422,000.00 |
| Mar 31, 2024 | -194,000.00 |
| Dec 31, 2023 | 1.58 Bn |
| Sep 30, 2023 | -1.17 Bn |
| Jun 30, 2023 | -587,000.00 |
| Mar 31, 2023 | -646,000.00 |
| Dec 31, 2022 | -1.05 Bn |
| Sep 30, 2022 | -994.44 Mn |
| Jun 30, 2022 | -3.38 Mn |
| Mar 31, 2022 | -834.77 Mn |
| Dec 31, 2021 | 1.45 Bn |
| Sep 30, 2021 | 1.43 Bn |
| Jun 30, 2021 | 1.41 Bn |